114 completed, 24 terminated, 7 withdrawn, 5 active not recruiting. 160 Phase 2, 42 Phase 1, 2 Phase 3.
Follow Carcinogenesis: new trials by email Literature Review of Carcinogenesis trials Research Report on Carcinogenesis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms Oral THU-decitabine - Myelofibrosis, MPN - Accelerated or Blast Phase | Phase 2 | Not yet recruiting | John Mascarenhas | 20 | 2027-01-01 | 2026-10-14 |
| Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia Bosutinib - Philadelphia Chromosome Positive CML, Accelerated Phase Chronic Myelogenous Leukemia | Phase 1 / Phase 2 | Active not recruiting | Children's Oncology Group | 60 | 2020-07-06 | 2026-10-01 |
| Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia Decitabine, Ponatinib, Venetoclax - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 20 | 2020-05-17 | 2026-06-05 |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation Vorinostat, Blood and Marrow Transplant (BMT), Tacrolimus (or cyclosporine) - Hematologic Diseases, Acute Leukemia in Remission | Phase 1 / Phase 2 | Active not recruiting | University of Michigan Rogel Cancer Center | 43 | 2020-02-04 | 2026-01-27 |
| Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors Ponatinib - Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | Incyte Biosciences International Sàrl | 70 | 2020-01-29 | 2026-10-09 |
| Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers Cladribine, Cytarabine, Dexrazoxane Hydrochloride - Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 100 | 2018-09-19 | 2026-05-22 |
| Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia Dexamethasone, Ponatinib Hydrochloride, Rituximab - Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 9 | 2018-06-26 | 2025-05-08 |
| Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia Blinatumomab, Cyclophosphamide, Cytarabine - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 22 | 2018-02-08 | 2026-08-19 |
| Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia Blinatumomab, Cytarabine, Methotrexate - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 90 | 2017-11-29 | 2026-05-20 |
| Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML Bosutinib, Inotuzumab Ozogamicin - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 22 | 2015-04-16 | 2023-07-17 |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 84 | 2015-03-23 | 2026-06-01 |
| Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia Cladribine, Cytarabine, Gilteritinib - Acute Biphenotypic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 508 | 2014-05-19 | 2026-05-20 |
| Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Bone Marrow Transplantation, Cyclophosphamide - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 54 | 2014-04-22 | 2024-01-24 |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children Allogeneic Hematopoietic Stem Cell Transplantation, Fludarabine Phosphate, Laboratory Biomarker Analysis - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 20 | 2014-04-10 | 2024-03-12 |
| Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies cyclophosphamide, fludarabine phosphate, mycophenolate mofetil - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 2 | Withdrawn | University of Medicine and Dentistry of New Jersey | 2014-01-01 | 2016-07-14 | |
| Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia Nilotinib, Ruxolitinib - Chronic Phase Chronic Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Completed | University Health Network, Toronto | 4 | 2013-08-01 | 2020-11-02 |
| Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies Aldesleukin, Allogeneic CD56-positive CD3-negative Natural Killer Cells, Allogeneic Hematopoietic Stem Cell Transplantation - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Erythroid Leukemia | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 63 | 2013-06-11 | 2023-11-07 |
| Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies therapeutic allogeneic lymphocytes, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 2 | Completed | University of Chicago | 77 | 2013-04-04 | 2019-08-07 |
| Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia nilotinib, rituximab, cyclophosphamide - B-cell Adult Acute Lymphoblastic Leukemia, Blastic Phase Chronic Myelogenous Leukemia | Phase 2 | Withdrawn | Mayo Clinic | 2012-12-01 | 2015-10-30 | |
| An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357) Dasatinib, Decitabine - Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 32 | 2012-06-12 | 2020-10-22 |
Showing 20 of 160. Sign in to see all of them.
Blast Crisis (159) · Leukemia, Myeloid, Accelerated Phase (109) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (104) · Leukemia, Myeloid, Acute (103) · Leukemia (100) · Leukemia, Myeloid, Chronic-Phase (82) · Myelodysplastic Syndromes (79) · Burkitt Lymphoma (67) · Leukemia, Lymphocytic, Chronic, B-Cell (67) · Lymphoma, Non-Hodgkin (65) · Lymphoma, Follicular (64) · Lymphoma, Mantle-Cell (64) · Lymphoma, Large B-Cell, Diffuse (62) · Congenital Abnormalities (61) · Lymphoma, B-Cell, Marginal Zone (60)
Neoplasms by Histologic Type (160) · Neoplastic Processes (160) · Pathologic Processes (160) · Pathological Conditions, Signs and Symptoms (160) · Bone Marrow Diseases (159) · Cell Transformation, Neoplastic (159) · Chronic Disease (159) · Disease Attributes (159) · Hemic and Lymphatic Diseases (159) · Leukemia, Myeloid (157) · Hematologic Diseases (156) · Neoplasms (154) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (115) · Immune System Diseases (114)
Cyclophosphamide (43) · Peripheral Blood Stem Cell Transplantation (42) · fludarabine phosphate (40) · Busulfan (34) · Methotrexate (33) · Tacrolimus (31) · Cyclosporine (25) · Cytarabine (24) · Mycophenolic Acid (24) · Antilymphocyte Serum (23) · Whole-Body Irradiation (21) · Filgrastim (18) · Radiotherapy (17) · Methylprednisolone (16) · Imatinib Mesylate (15)
Fred Hutchinson Cancer Center (31) · M.D. Anderson Cancer Center (19) · Memorial Sloan Kettering Cancer Center (10) · National Cancer Institute (NCI) (8) · Case Comprehensive Cancer Center (7) · Masonic Cancer Center, University of Minnesota (5) · Roswell Park Cancer Institute (5) · City of Hope Medical Center (4) · H. Lee Moffitt Cancer Center and Research Institute (4) · Asan Medical Center (3) · Children's Oncology Group (3) · Jonsson Comprehensive Cancer Center (3) · Northside Hospital, Inc. (3) · UNC Lineberger Comprehensive Cancer Center (3) · University of Maryland, Baltimore (3)
United States (140) · Italy (9) · Canada (8) · France (7) · Germany (7) · South Korea (4) · Switzerland (4) · Belgium (3) · Netherlands (3) · United Kingdom (3) · Australia (2) · Denmark (2) · Spain (2) · Sweden (2) · Austria (1)
Ann E. Woolfrey, MD (3) · Claudio Anasetti, MD (3) · Elias Jabbour (3) · Kyoo H. Lee, MD (3) · Philip L. McCarthy, MD (3) · Sergio Giralt, MD (3) · Brenda Sandmaier (2) · Brenda W. Cooper, MD (2) · Claudio G. Brunstein, MD, PhD (2) · David G. Savage, MD (2) · Jorge Cortes, MD (2) · Marie Bleakley (2) · Paul Carpenter, MD (2)
PMID 32499241, PMID 35007144, PMID 15107815, PMID 17910637, PMID 18327587, PMID 18769450, PMID 18838477, PMID 18989154, PMID 18997171, PMID 19139736, PMID 19179301, PMID 19286996, PMID 19706886, PMID 19841031, PMID 1994541, PMID 20124511, PMID 20466853, PMID 20858843, PMID 21403127, PMID 21508120, PMID 21523798, PMID 21715313, PMID 22002488, PMID 22430088, PMID 24362550, PMID 25085357, PMID 25939707, PMID 26210442, PMID 26432046, PMID 26764356, PMID 29702001, PMID 30501869, PMID 34312462, PMID 34329576, PMID 36402146, PMID 36600670, PMID 38033284, PMID 39028925, PMID 39303729, PMID 40193193, PMID 40369607, PMID 40500616, PMID 42784255, PMID 7632970, PMID 8417795
P30CA015704 (9), P30CA043703 (6), P01CA018029 (5), P30CA016672 (4), N01CM62202 (3), P01CA078902 (3), P30CA036727 (3), 2023 (2), P01HL036444 (2), P30CA006973 (2), P30CA016058 (2), P30CA016086 (2), P30CA033572 (2), R01HL121568 (2), 2005 (1)